Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Infertility Drugs Market

Infertility Drugs Market Trends

Report ID: GMI5892
Published Date: May 2023
Report Format: PDF

Download Free Sample

Infertility Drugs Market Trends

The increasing prevalence of infertility worldwide is one of the significant growth drivers for the market. For instance, according to the World Health Organization (WHO) report, around 17.5% of the adult population or roughly 1 in 6 individual worldwide experience infertility, showing the urgent need to increase access to affordable, high-quality fertility care for those in necessity. Also, various factors contribute to the rising incidence of infertility, including lifestyle changes, delayed pregnancies, environmental factors, and medical conditions such as polycystic ovary syndrome (PCOS) and endometriosis. Such factors will supplement the market development. Furthermore, as the global population continues to age and fertility rates decline, the demand for infertility treatments and drugs is expected to surge in a forthcoming year.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Infertility drugs industry accounted for more than USD 3.5 billion in 2022 and is estimated to reach over USD 6 billion by end of 2032, on account of numerous programs launched by the governments to help people with infertility problems, as well as availability of insurance coverage for therapy.

The parenteral route of administration will generate revenue worth over USD 3.5 billion by end of 2032, as injections and intravenous infusion offer direct & rapid delivery of infertility drugs into the bloodstream, ensuring more efficient & predictable absorption of the drugs, faster onset of action, and improved treatment outcomes.

North America accounted for 43% share in infertility drugs industry in 2022 and will grow at considerable rate through 2032, owing to increasing adoption of a sedentary lifestyle by both women and men leading to infertility issues.

Merck KGaA, Ferring B.V., Abbott, Livzon, Pfizer Inc., Mankind Pharma, Teva Pharmaceutical Industries Ltd., and IBSA Institut Biochimique SA among others.